Further explorations in prospective studies, larger cohorts and/or of biomarker disease specificity are required to determine the relevance of the level of LAMP2 as a measure reflecting the neuropathology of AD or other neurodegenerative diseases. This evidence concerns the gene LAMP2 and neurodegenerative disease.